title: Evaluation of the effects of bovine hemoglobin glutamer-200 on systolic arterial blood pressure in hypotensive cats: 44 cases (1997-2008).
abstract: OBJECTIVE
  To determine effects of bovine hemoglobin glutamer-200 (Hb-200) solution on systolic arterial blood pressure (SAP) in hypotensive cats and describe potential adverse effects associated with this treatment.
  
  
  METHODS
  Retrospective case series.
  
  
  METHODS
  44 cats.
  
  
  METHODS
  Medical records of hypotensive (Doppler SAP ≤ 80 mm Hg) cats that received Hb-200 treatment were reviewed. Volume and rate of Hb-200 administration, treatments for hypotension given prior to Hb-200 administration, changes in SAP, potential adverse effects, and short-term outcome were evaluated.
  
  
  RESULTS
  44 cats were included in the study. Mean ± SD SAP prior to Hb-200 administration was 52 ± 11 mm Hg, despite other treatments. Forty-three cats received Hb-200 via IV bolus administration (mean ± SD volume, 3.1 ± 2.2 mL/kg [1.41 ± 1.0 mL/lb] over 25.17 ± 17.51 minutes); 1 cat received a continuous rate infusion (CRI) only. The SAP increased to > 80 mm Hg in 33 of 44 (75%) cats. The SAP increased > 20 mm Hg above baseline value in 29 of these 33 cats and in 4 cats in which SAP did not exceed 80 mm Hg. A CRI (mean ± SD rate, 0.8 ± 0.5 mL/kg/h [0.36 ± 0.23 mL/lb/h]) of Hb-200 was administered to 37 cats (after bolus infusion in 36). Mean SAP during the CRI was 92 ± 18 mm Hg. Adverse effects included respiratory changes (n = 8 cats), vomiting (2), and pigmented serum (30). Seventeen (39%) cats survived to discharge from the hospital, 6 died, and 21 were euthanized.
  
  
  CONCLUSIONS
  Hb-200 effectively increased SAP in hypotensive cats with few adverse effects.
authors: Animal Emergency Clinic, Oakdale, MN 55128, USA. weha0001@umn.edu
authors: Conni E
authors: CE
authors: Wehausen
authors: Rebecca
authors: R
authors: Kirby
authors: Elke
authors: E
authors: Rudloff
mesh_terms: D000818:Animals; D001802:Blood Substitutes / Q000009:adverse effects / Q000627:therapeutic use*; D002371:Cat Diseases / Q000188:drug therapy*; D002415:Cats; D003102:Colloids / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006454:Hemoglobins / Q000009:adverse effects / Q000627:therapeutic use*; D007022:Hypotension / Q000188:drug therapy / Q000662:veterinary*; D008297:Male; D012189:Retrospective Studies
chemical_list: D001802:Blood Substitutes; D003102:Colloids; D006454:Hemoglobins; C402601:hemoglobin glutamer-200